TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07777484: An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination in Individuals Who Have Previously Undergone aSyn Immunotherapy

Sponsor: Tridem Bioscience FlexCo · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,206,400

Rescue Site Savings

+$7,389,220

Unlock Full NCT07777484 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07777484 Rescue Dossier →